| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 143, 1072-1085, Copyright © 1993 by American Society for Investigative Pathology
REGULAR ARTICLES |
SJ Hamilton-Dutoit, D Rea, M Raphael, K Sandvej, HJ Delecluse, C Gisselbrecht, L Marelle, HJ van Krieken and G Pallesen
Laboratory of Immunohistology, Aarhus University Hospital, Denmark.
We investigated 49 acquired immunodeficiency syndrome-related lymphomas (ARLs) for Epstein-Barr virus (EBV) by Southern blotting and in situ hybridization and, in positive cases, used cryostat immunohistology to compare EBV-latent gene expression (EBV encoded small RNA-1 [EBER-1], EBV nuclear antigen-2 [EBNA-2], latent membrane protein-1 [LMP-1] and host cell immunophenotype (CD11a, CD18, CD54, CD58, CD21, CD23, CD30, CD39, CDw70, immunoglobulin) patterns with those reported in other EBV infections. EBV+ immunoblast-rich/large cell ARLs (n = 22) showed three patterns of latency: broad (EBER+EBNA-2+/LMP-1+; n = 9), reminiscent of a lymphoblastoid cell line phenotype; restricted (EBER+/EBNA-2-/LMP-1-; n = 6), similar to endemic Burkitt's lymphoma; and intermediate (EBER+/EBNA-2-/LMP-1+; n = 7), a pattern rarely described in vitro but seen in certain EBV-related malignancies. EBNA-2 expression was associated with extranodal lymphomas. EBV+ Burkitt-type ARLs (n = 11) usually showed the restricted latency pattern (n = 8), but some expressed the intermediate form (n = 3). Adhesion (CD54, CD58) and activation (CD30, CD39, CDw70) molecule expression varied with morphology (immunoblast-rich/large cell versus Burkitt-type), but was not independently correlated with EBV-positivity. CD30 and LMP-1 expression were associated. ARLs show heterogeneity regarding both the presence of EBV and latency pattern. Comparison of these phenotypically distinct lymphoma groups with known forms of EBV infection provides clues to their possible pathogenesis.
This article has been cited by other articles:
 |
|
 |
|
  I. Guasparri, D. Bubman, and E. Cesarman EBV LMP2A affects LMP1-mediated NF-{kappa}B signaling and survival of lymphoma cells by regulating TRAF2 expression Blood, April 1, 2008; 111(7): 3813 - 3820. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bhaduri-McIntosh, M. J. Rotenberg, B. Gardner, M. Robert, and G. Miller Repertoire and frequency of immune cells reactive to Epstein-Barr virus-derived autologous lymphoblastoid cell lines Blood, February 1, 2008; 111(3): 1334 - 1343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. F. Israel, M. Gulley, S. Elmore, S. Ferrini, W.-h. Feng, and S. C. Kenney Anti-CD70 antibodies: a potential treatment for EBV+ CD70-expressing lymphomas Mol. Cancer Ther., December 1, 2005; 4(12): 2037 - 2044. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. T. Lim and A. M. Levine Recent Advances in Acquired Immunodeficiency Syndrome (AIDS)-related Lymphoma CA Cancer J Clin, July 1, 2005; 55(4): 229 - 241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. H. Gudgeon, G. S. Taylor, H. M. Long, T. A. Haigh, and A. B. Rickinson Regression of Epstein-Barr Virus-Induced B-Cell Transformation In Vitro Involves Virus-Specific CD8+ T Cells as the Principal Effectors and a Novel CD4+ T-Cell Reactivity J. Virol., May 1, 2005; 79(9): 5477 - 5488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Katano, L. Pesnicak, and J. I. Cohen Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas PNAS, April 6, 2004; 101(14): 4960 - 4965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Kurth, M.-L. Hansmann, K. Rajewsky, and R. Kuppers Epstein-Barr virus-infected B cells expanding in germinal centers of infectious mononucleosis patients do not participate in the germinal center reaction PNAS, April 15, 2003; 100(8): 4730 - 4735. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kahnt, K. Matz-Rensing, P. Hofmann, C. Stahl-Hennig, and F.-J. Kaup SIV-associated Lymphomas in Rhesus Monkeys (Macaca mulatta) in Comparison with HIV-associated Lymphomas Vet. Pathol., January 1, 2002; 39(1): 42 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. F. Israel, R. J. Pickles, D. M. Segal, R. D. Gerard, and S. C. Kenney Enhancement of Adenovirus Vector Entry into CD70-Positive B-Cell Lines by Using a Bispecific CD70-Adenovirus Fiber Antibody J. Virol., June 1, 2001; 75(11): 5215 - 5221. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. L. Gulley Molecular Diagnosis of Epstein-Barr Virus-Related Diseases J. Mol. Diagn., February 1, 2001; 3(1): 1 - 10. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. L. Hecht and J. C. Aster Molecular Biology of Burkitt's Lymphoma J. Clin. Oncol., November 1, 2000; 18(21): 3707 - 3721. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Westphal, W. Blackstock, W. Feng, B. Israel, and S. C. Kenney Activation of Lytic Epstein-Barr Virus (EBV) Infection by Radiation and Sodium Butyrate in Vitro and in Vivo: A Potential Method for Treating EBV-positive Malignancies Cancer Res., October 1, 2000; 60(20): 5781 - 5788. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. F. Dukers, P. Meij, M. B. H. J. Vervoort, W. Vos, R. J. Scheper, C. J. L. M. Meijer, E. Bloemena, and J. M. Middeldorp Direct Immunosuppressive Effects of EBV-Encoded Latent Membrane Protein 1 J. Immunol., July 15, 2000; 165(2): 663 - 670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. Murray, C. M. Constandinou, J. Crocker, L. S. Young, and R. F. Ambinder Analysis of Major Histocompatibility Complex Class I, TAP Expression, and LMP2 Epitope Sequence in Epstein-Barr Virus-Positive Hodgkin's Disease Blood, October 1, 1998; 92(7): 2477 - 2483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Kenney, M. E. Guinness, T. Curiel, and J. Lacy Antisense to the Epstein-Barr Virus (EBV)-Encoded Latent Membrane Protein 1 (LMP-1) Suppresses LMP-1 and Bcl-2 Expression and Promotes Apoptosis in EBV-Immortalized B Cells Blood, September 1, 1998; 92(5): 1721 - 1727. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Larocca, D. Capello, A. Rinelli, S. Nori, A. Antinori, A. Gloghini, A. Cingolani, A. Migliazza, G. Saglio, S. Cammilleri-Broet, et al. The Molecular and Phenotypic Profile of Primary Central Nervous System Lymphoma Identifies Distinct Categories of the Disease and Is Consistent With Histogenetic Derivation From Germinal Center-Related B Cells Blood, August 1, 1998; 92(3): 1011 - 1019. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Tao, K. D. Robertson, A. Manns, A. Hildesheim, and R. F. Ambinder Epstein-Barr Virus (EBV) in Endemic Burkitt's Lymphoma: Molecular Analysis of Primary Tumor Tissue Blood, February 15, 1998; 91(4): 1373 - 1381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Carbone, G. Gaidano, A. Gloghini, L. M. Larocca, D. Capello, V. Canzonieri, A. Antinori, U. Tirelli, B. Falini, and R. Dalla-Favera Differential Expression of BCL-6, CD138/Syndecan-1, and Epstein-Barr Virus-Encoded Latent Membrane Protein-1 Identifies Distinct Histogenetic Subsets of Acquired Immunodeficiency Syndrome-Related Non-Hodgkin's Lymphomas Blood, February 1, 1998; 91(3): 747 - 755. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Horenstein, R. G. Nador, A. Chadburn, E. M. Hyjek, G. Inghirami, D. M. Knowles, and E. Cesarman Epstein-Barr Virus Latent Gene Expression in Primary Effusion Lymphomas Containing Kaposi's Sarcoma-Associated Herpesvirus/Human Herpesvirus-8 Blood, August 1, 1997; 90(3): 1186 - 1191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Quintanilla-Martinez, C. Lome-Maldonado, G. Ott, A. Gschwendtner, E. Gredler, E. Reyes, A. Angeles-Angeles, and F. Fend Primary Non-Hodgkin's Lymphoma of the Intestine: High Prevalence of Epstein-Barr Virus in Mexican Lymphomas as Compared With European Cases Blood, January 15, 1997; 89(2): 644 - 651. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
